MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash acquired in
connection with reverse...
$40,855K
Issuance of common stock
$15,000K
Proceeds from long-term
debt
$647K
Net cash provided by
financing activities
$44,748K
Canceled cashflow
$11,754K
Net increase in cash
and equivalents
$19,402K
Canceled cashflow
$25,346K
Repayment of short-term
debt
$11,250K
Deferred financing costs
$504K
Net cash (used in)
provided by operating...
-$16,315K
Net cash used in
investing activities
-$8,985K
Effect of currency
exchange rate changes on...
-$46K
Depreciation and
amortization
$4,228K
Amortization of deferred
financing fees
$439K
Loss on impairment of
assets
$34K
Total adjustments
-$9,593K
Net loss
-$6,722K
Capital expenditures
$8,985K
Canceled cashflow
$4,701K
Accounts payable
-$4,533K
Receivables
$3,415K
Inventories
$3,321K
Other current assets
$1,769K
Accrued liabilities
-$901K
Other
-$355K
Back
Back
Cash Flow
source: myfinsight.com
ENZON PHARMACEUTICALS, INC. (ENZN)
ENZON PHARMACEUTICALS, INC. (ENZN)